通化东宝：甘精胰岛素注射液获得缅甸上市许可

Core Viewpoint - Tonghua Dongbao (600867.SH) has received approval from the Ministry of Health of the Republic of the Union of Myanmar for the marketing of its product, Insulin Glargine Injection, which is a long-acting insulin analog that helps to stabilize blood sugar levels in patients [1] Group 1 - The product Insulin Glargine is designed to provide a steady reduction in blood sugar levels for patients [1] - In 2024, the average annual expenditure related to diabetes for patients in Myanmar is projected to be $164.1 [1]